Five things for pharma marketers to know: Thursday, March 24, 2016



1. One month after California legalized physician-assisted suicide, Valeant Pharmaceuticals doubled the price of Seconal — one of the longest used drugs to help terminally ill patients end their lives. (ABC)

2. Bristol-Myers Squibb announced it would acquire Padlock Therapeutics. Padlock has a program aimed at developing drugs for rheumatoid arthritis and other autoimmune diseases. The deal is worth up to $600 million. (Boston Globe)

3. Roche is looking to form more partnerships with other drugmakers ahead of the potential approval of its experimental cancer drug atezolizumab. The company has already announced collaborations with Kite Pharma and Johnson & Johnson. (Bloomberg)

4. The FDA approved Teva's asthma drug Cinqair (reslizumab), a new treatment for patients with severe asthma. Cinqair is given intravenously every four weeks in combination with a number of other drugs. (Reuters)

5. ICYMI: The FDA will require all fast-acting opioid-based pain medications to carry a black box warning that these drugs potentially put patients at risk for abuse, addiction, overdose, and death. (NPR)

close

Next Article in Commercial